EZH2 and Miyoshi myopathy: Furthermore, data from utilizing epigenetic inhibitors targeting several epigenetic modifiers e.g., DNMTs, HDACs, EZH2, BMI-1, and BET bromodomains have shown pleiotropic anti-MM effects by affecting several oncogenic pathways using MM in vitro and in vivo models.